GlassScriptPhysician profile
Madison Plaska
NPI 1871243683
$1,053.77
in general payments reported to CMS, 2019-2025
11 companies · $86.29 in 2025
The $86.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $596 · 2024: $112 · 2025: $86.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.35 |
| Education | $393.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $330.87 | 2022-2023 | Xospata, Xtandi |
| Novartis Pharmaceuticals Corporation | $236.61 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.30 | 2022-2023 | Ninlaro |
| Seagen INC. | $99.00 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $95.00 | 2023 | Imbruvica |
| Lilly USA, LLC | $82.49 | 2022 | |
| Mirati Therapeutics, INC. | $32.88 | 2023 | Krazati |
| Abbvie INC. | $27.74 | 2024 | |
| Pfizer INC. | $19.58 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.03 | 2023 | Calquence |
| Gilead Sciences, INC. | $13.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Plaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.